Eisai shutters oncology unit, cuts around 80 jobs
Days after announcing a reorganization plan to focus on deep learning and its “most important project,” the Biogen-partnered Alzheimer’s drug lecanemab, Eisai is shuttering its oncology unit H3 Biomedicine.
The news comes after H3 revealed in public documents last week that it’s laying off employees at its Cambridge, MA, headquarters. In total, 88 jobs will be affected, a spokesperson said. According to Massachusetts public documents, at least 79 will be laid off by Sept. 15.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.